UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 104

Sortiert nach

Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial

Journal of bone and mineral research, 2004-08, Vol.19 (8), p.1250-1258

2004

Volltextzugriff (PDF)

Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women

Osteoporosis international, 2005-05, Vol.16 (5), p.468-474

2005

Volltextzugriff (PDF)

Effect of Alendronate on the Age‐Specific Incidence of Symptomatic Osteoporotic Fractures

Journal of bone and mineral research, 2005-06, Vol.20 (6), p.971-976

2005

Volltextzugriff (PDF)

Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents

The journal of clinical endocrinology and metabolism, 2002-04, Vol.87 (4), p.1586-1592

2002

Volltextzugriff (PDF)

Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study

Journal of bone and mineral research, 2005-01, Vol.20 (1), p.141-151

2005

Volltextzugriff (PDF)

Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years

The journal of clinical endocrinology and metabolism, 2006-07, Vol.91 (7), p.2631-2637

2006

Volltextzugriff (PDF)

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

JAMA : the journal of the American Medical Association, 1998-12, Vol.280 (24), p.2077

1998

Volltextzugriff (PDF)

Vertebral Fracture Prevalence Among Women Screened for the Fracture Intervention Trial and a Simple Clinical Tool to Screen for Undiagnosed Vertebral Fractures

Mayo Clinic proceedings, 2000-09, Vol.75 (9), p.888-896

2000

Volltextzugriff (PDF)

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures

The Lancet (British edition), 1996-12, Vol.348 (9041), p.1535-1541

1996

Volltextzugriff (PDF)

Prevalent Vertebral Deformities Predict Mortality and Hospitalization in Older Women with Low Bone Mass

Journal of the American Geriatrics Society (JAGS), 2000-03, Vol.48 (3), p.241-249

2000

Volltextzugriff (PDF)

Effect of Alendronate on Vertebral Fracture Risk in Women With Bone Mineral Density T Scores of −1.6 to −2.5 at the Femoral Neck: The Fracture Intervention Trial

Mayo Clinic proceedings, 2005-03, Vol.80 (3), p.343-349

2005

Volltextzugriff (PDF)

Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987

Radiation research, 1994-02, Vol.137 (2 Suppl), p.S17

1994

Volltextzugriff (PDF)

Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987

Radiation research, 1994-02, Vol.137 (2 Suppl), p.S68

1994

Volltextzugriff (PDF)

Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis

Bone (New York, N.Y.), 2003-07, Vol.33 (1), p.150-158

2003

Volltextzugriff (PDF)

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis

Current medical research and opinion, 2004-12, Vol.20 (12), p.2031-2041

2004

Volltextzugriff (PDF)

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

The journal of clinical endocrinology and metabolism, 2002-04, Vol.87 (4), p.1586-1592

2002

Volltextzugriff (PDF)

Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years

Obstetrical & gynecological survey, 2007-01, Vol.62 (1), p.35-36

2007

Volltextzugriff (PDF)

Cancer incidence in atomic bomb survivors. Part IV: Comparison of cancer incidence and mortality

Radiation research, 1994-02, Vol.137 (2 Suppl), p.S98

1994

Volltextzugriff (PDF)

Cancer incidence in atomic bomb survivors. Part I: Use of the tumor registries in Hiroshima and Nagasaki for incidence studies

Radiation research, 1994-02, Vol.137 (2 Suppl), p.S1

1994

Volltextzugriff (PDF)

Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial

The journal of clinical endocrinology and metabolism, 2000-11, Vol.85 (11), p.4118-4124

2000

Volltextzugriff (PDF)

Fracture Risk Reduction With Alendronate in Women With Osteoporosis: The Fracture Intervention Trial

Obstetrical & gynecological survey, 2001-05, Vol.56 (5), p.284-285

2001

Volltextzugriff (PDF)

Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial

The American journal of medicine, 1996-10, Vol.101 (4), p.341-348

1996

Volltextzugriff (PDF)

Alendronate and Vertebral Fracture Risk: In Response

Mayo Clinic proceedings, 2005-09, Vol.80 (9), p.1238-1240

2005

Volltextzugriff (PDF)

Alendronate and Vertebral Fracture Risk

Mayo Clinic proceedings, 2005, Vol.80 (9), p.1238,1240-1238,1240

2005

Volltextzugriff (PDF)

Alendronate and Vertebral Fracture Risk

Mayo Clinic proceedings, 2005-09, Vol.80 (9), p.1236-1236

2005

Volltextzugriff (PDF)

1 – 25 von 104

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(97)
Reviews
(6)
Berichte
(1)

Sprache

Englisch
(104)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial

Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women

Effect of Alendronate on the Age‐Specific Incidence of Symptomatic Osteoporotic Fractures

Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents

Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study

Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

Vertebral Fracture Prevalence Among Women Screened for the Fracture Intervention Trial and a Simple Clinical Tool to Screen for Undiagnosed Vertebral Fractures

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures

Prevalent Vertebral Deformities Predict Mortality and Hospitalization in Older Women with Low Bone Mass

Effect of Alendronate on Vertebral Fracture Risk in Women With Bone Mineral Density T Scores of −1.6 to −2.5 at the Femoral Neck: The Fracture Intervention Trial

Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987

Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987

Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years

Cancer incidence in atomic bomb survivors. Part IV: Comparison of cancer incidence and mortality

Cancer incidence in atomic bomb survivors. Part I: Use of the tumor registries in Hiroshima and Nagasaki for incidence studies

Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial

Fracture Risk Reduction With Alendronate in Women With Osteoporosis: The Fracture Intervention Trial

Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial

Alendronate and Vertebral Fracture Risk: In Response

Alendronate and Vertebral Fracture Risk

Alendronate and Vertebral Fracture Risk

Suchergebnisse filtern